ADM vs REGN · P/E 34, rev $85.53B vs P/E 14, rev $14.34B
Archer-Daniels-Midland Company (ADM) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Archer-Daniels-Midland Company (ADM) is a farm products company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported ADM revenue for 2024-12-31 was $85.53B. Net income was $1.78B. Revenue was up 272.2% from 2023-12-31 to 2024-12-31. ADM currently screens at market cap $36.87B and trailing P/E 34.2.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
ADM currently screens at market cap $36.87B and trailing P/E 34.2. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the ADM and REGN stock pages for the full models.
Not investment advice.